Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies

NCT07341867 is registered in ClinicalTrials.gov with Andrew Hantel, MD as lead sponsor.

NCT NCT07341867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07341867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies
Lead sponsor
Andrew Hantel, MD
Phase
Phase 1
Overall status
Recruiting
Start date
July 30, 2026
Completion date
March 31, 2029
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

duffy blood group, chemokine receptor gene c.-67t>c, duffy blood group, chemokine receptor gene mutation, multiple myeloma, triple negative breast cancer